Page last updated: 2024-09-04

lubiprostone and Atherogenesis

lubiprostone has been researched along with Atherogenesis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arakawa, K; Chen, L; Doi, H; Hibi, K; Ishigami, T; Kimura, K; Kino, T; Minegishi, S; Nakai-Sugiyama, M; Saigoh-Teranaka, S; Sasaki-Nakashima, R; Tamura, K	1

Other Studies

1 other study(ies) available for lubiprostone and Atherogenesis

Article	Year
Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PloS one, 2019, Volume: 14, Issue:6 Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Chloride Channel Agonists; Chloride Channels; CLC-2 Chloride Channels; Cytokines; Diet, Western; Disease Models, Animal; Ileum; Immunoglobulins; Inflammation; Intestinal Mucosa; Lubiprostone; Mice; Mice, Inbred C57BL; Occludin; Permeability; Tight Junction Proteins; Zonula Occludens-1 Protein	2019

Article

Year

Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.

PloS one, 2019, Volume: 14, Issue:6

Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Chloride Channel Agonists; Chloride Channels; CLC-2 Chloride Channels; Cytokines; Diet, Western; Disease Models, Animal; Ileum; Immunoglobulins; Inflammation; Intestinal Mucosa; Lubiprostone; Mice; Mice, Inbred C57BL; Occludin; Permeability; Tight Junction Proteins; Zonula Occludens-1 Protein

2019